Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Treatment Characteristics: Dosing Patterns - Dose Reductions During Treatment With BLENREP Therapy

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Number of participants for whom BLENREP dosing was dose reduced during treatment as categorized by reason.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Reported measurements

Total # of Participants with Dose Reductions for Any Reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants19Not reportedNot reportedNot reportedNot reported
Dose Reduction for Corneal Adverse Event
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants13Not reportedNot reportedNot reportedNot reported
Dose Reduction for Hematologic Toxicity
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants6Not reportedNot reportedNot reportedNot reported
Dose Reduction for Other Reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        19
    title
    Total # of Participants with Dose Reductions for Any Reason
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    Dose Reduction for Corneal Adverse Event
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Dose Reduction for Hematologic Toxicity
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Dose Reduction for Other Reason
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Number of participants for whom BLENREP dosing was dose reduced during treatment as categorized by reason.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Treatment Characteristics: Dosing Patterns - Dose Reductions During Treatment With BLENREP Therapy
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice